India · Delayed Price · Currency is INR Vilin Bio Med Statistics
Total Valuation
Vilin Bio Med has a market cap or net worth of INR 777.75 million. The enterprise value is 765.11 million.
| Market Cap | 777.75M |
| Enterprise Value | 765.11M |
Important Dates
The next estimated earnings date is Friday, October 30, 2026.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Vilin Bio Med has 15.25 million shares outstanding. The number of shares has increased by 9.32% in one year.
| Current Share Class | 15.25M |
| Shares Outstanding | 15.25M |
| Shares Change (YoY) | +9.32% |
| Shares Change (QoQ) | +21.16% |
| Owned by Insiders (%) | 55.02% |
| Owned by Institutions (%) | n/a |
| Float | 6.86M |
Valuation Ratios
The trailing PE ratio is 42.02.
| PE Ratio | 42.02 |
| Forward PE | n/a |
| PS Ratio | 1.91 |
| PB Ratio | 2.85 |
| P/TBV Ratio | 2.85 |
| P/FCF Ratio | 201.37 |
| P/OCF Ratio | 115.70 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 24.88, with an EV/FCF ratio of 198.22.
| EV / Earnings | 41.21 |
| EV / Sales | 1.88 |
| EV / EBITDA | 24.88 |
| EV / EBIT | 27.32 |
| EV / FCF | 198.22 |
Financial Position
The company has a current ratio of 4.25, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.25 |
| Quick Ratio | 2.71 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.06 |
| Debt / FCF | 0.51 |
| Interest Coverage | 43.17 |
Financial Efficiency
Return on equity (ROE) is 7.50% and return on invested capital (ROIC) is 7.29%.
| Return on Equity (ROE) | 7.50% |
| Return on Assets (ROA) | 5.80% |
| Return on Invested Capital (ROIC) | 7.29% |
| Return on Capital Employed (ROCE) | 10.21% |
| Weighted Average Cost of Capital (WACC) | 7.77% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 1.35 |
| Inventory Turnover | 6.48 |
Taxes
In the past 12 months, Vilin Bio Med has paid 9.12 million in taxes.
| Income Tax | 9.12M |
| Effective Tax Rate | 32.10% |
Stock Price Statistics
The stock price has increased by +99.61% in the last 52 weeks. The beta is 0.63, so Vilin Bio Med's price volatility has been lower than the market average.
| Beta (5Y) | 0.63 |
| 52-Week Price Change | +99.61% |
| 50-Day Moving Average | 48.57 |
| 200-Day Moving Average | 37.30 |
| Relative Strength Index (RSI) | 46.51 |
| Average Volume (20 Days) | 25,600 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Vilin Bio Med had revenue of INR 422.63 million and earned 19.29 million in profits. Earnings per share was 1.26.
| Revenue | 422.63M |
| Gross Profit | 46.08M |
| Operating Income | 29.10M |
| Pretax Income | 28.41M |
| Net Income | 19.29M |
| EBITDA | 31.94M |
| EBIT | 29.10M |
| Earnings Per Share (EPS) | 1.26 |
Balance Sheet
The company has 14.70 million in cash and 2.06 million in debt, with a net cash position of 12.64 million or 0.83 per share.
| Cash & Cash Equivalents | 14.70M |
| Total Debt | 2.06M |
| Net Cash | 12.64M |
| Net Cash Per Share | 0.83 |
| Equity (Book Value) | 283.73M |
| Book Value Per Share | 18.60 |
| Working Capital | 209.41M |
Cash Flow
In the last 12 months, operating cash flow was 6.98 million and capital expenditures -2.97 million, giving a free cash flow of 4.01 million.
| Operating Cash Flow | 6.98M |
| Capital Expenditures | -2.97M |
| Depreciation & Amortization | 2.85M |
| Net Borrowing | -23.67M |
| Free Cash Flow | 4.01M |
| FCF Per Share | 0.26 |
Margins
Gross margin is 10.90%, with operating and profit margins of 6.88% and 4.56%.
| Gross Margin | 10.90% |
| Operating Margin | 6.88% |
| Pretax Margin | 6.72% |
| Profit Margin | 4.56% |
| EBITDA Margin | 7.56% |
| EBIT Margin | 6.88% |
| FCF Margin | 0.95% |
Dividends & Yields
Vilin Bio Med does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -9.32% |
| Shareholder Yield | -9.32% |
| Earnings Yield | 2.39% |
| FCF Yield | 0.50% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Vilin Bio Med has an Altman Z-Score of 5.81 and a Piotroski F-Score of 5.
| Altman Z-Score | 5.81 |
| Piotroski F-Score | 5 |